Dr. Paika Podcast

Mohammed Paika
  • 5.0 (2)
  • Medicine

Welcome to the Dr. Paika Podcast — where medicine, fitness, and humanity come together. Hosted by Dr. Mohammed K. Paika, M.D., double board-certified in obesity & internal medicine with close to 20 years of hospital experience, this show dives deep into the science of health, obesity, longevity, and mindset — but with compassion, not complexity. From hospital medicine to the gym floor, from patient care to personal growth — every episode blends real clinical insight with practical, inspiring stories that help you live better and think deeper. 💡 Topics include: Obesity & metabolic health Longevity & fitness Nutrition & preventive medicine Doctor insights from close to 20 years in hospitals across the US! Mindset, mental health, and motivation 🎧 Subscribe for weekly conversations that are honest, empowering, and rooted in science — all from a doctor who believes medicine should heal the mind and body.

  1. 6h ago

    Why Ozempic and Zepbound Wake You Up at 3 AM (Doctor Explains)

    #GLP1 #Ozempic #Zepbound #Insomnia #SleepApnea Waking up at 3 AM on Ozempic, Wegovy, Mounjaro or Zepbound? You’re not imagining it, and the medicine usually isn’t the whole story. In the trial that got Zepbound approved for sleep apnea, people on the drug actually reported better sleep than people on placebo. So when your sleep gets worse, something the drug changes in your body is often what’s waking you up. In this video, I’m Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. I go through 6 possible causes of 3 AM wake-ups on a GLP-1, what the research actually shows for each one, and what you can change starting tonight: 📘 FREE GLP-1 Diet Cookbook: join my newsletter at https://www.drmohammedpaika.com🎓 GLP-1 Masterclass (side effects, protein and calorie targets, and a 12-week home exercise program): https://www.drmohammedpaika.com TIMESTAMPS0:00 Waking up at 3 AM on a GLP-11:06 Who this video is for1:36 My story: what bad sleep did to me2:52 The patient who blamed their GLP-13:30 Your best clue: the first minute after you wake4:01 Cause 1: Low blood sugar at night5:35 Cause 2: Night reflux8:16 Cause 3: A faster heart rate9:09 Cause 4: Alcohol10:10 Cause 5: Sleep apnea you don’t know you have11:50 Cause 6: Hunger, water timing & the drug itself13:24 The 30-second scorecard13:41 Your 1-week plan14:30 When to call your prescriber15:14 What you need besides this15:45 Up next REFERENCES Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193-1205. https://pubmed.ncbi.nlm.nih.gov/38912654/Kanu C, et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants. Sleep Med. 2025;134:106719. https://pubmed.ncbi.nlm.nih.gov/40774158/Malhotra A, et al. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: time course and association with body weight. Sleep Med. 2025;136:106853. https://pubmed.ncbi.nlm.nih.gov/41135142/FDA approves Zepbound for obstructive sleep apnea in adults with obesity (Dec 20, 2024). https://www.pharmacist.com/Blogs/CEO-Blog/fda-approves-zepbound-for-obstructive-sleep-apneaKamalinia S, et al. Risk of any hypoglycaemia with newer antihyperglycaemic agents in type 2 diabetes. Endocrinol Diabetes Metab. 2019;3:e00100. https://pubmed.ncbi.nlm.nih.gov/31922027/Katranski J, et al. Psychiatric adverse events linked to GLP-1 analogues. Int J Clin Pharm. 2025;47:1739-1747. https://pubmed.ncbi.nlm.nih.gov/40522403/Nong K, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025;390:e083039. https://pubmed.ncbi.nlm.nih.gov/40813122/Mayo Clinic. Diabetic hypoglycemia: symptoms and causes. https://www.mayoclinic.org/diseases-conditions/diabetic-hypoglycemia/symptoms-causes/syc-20371525Noh Y, et al. GLP-1 receptor agonists and risk for gastroesophageal reflux disease in type 2 diabetes. Ann Intern Med. 2025;178:1268-1278. https://pubmed.ncbi.nlm.nih.gov/40658955/Liu BD, et al. Shorter-acting GLP-1 receptor agonists and gastro-oesophageal reflux disease. Gut. 2024;73:246-254. https://pubmed.ncbi.nlm.nih.gov/37739778/Hiramoto B, et al. Quantified metrics of gastric emptying delay by GLP-1 agonists: a meta-analysis. Am J Gastroenterol. 2024;119:1126-1140. https://pubmed.ncbi.nlm.nih.gov/38634551/Hoshino S, et al. Nocturnal gastroesophageal reflux and sleep depth in healthy adults. J Nippon Med Sch. 2024;91:371-376. https://pubmed.ncbi.nlm.nih.gov/39231640/Fujiwara Y, et al. Association between dinner-to-bed time and gastro-esophageal reflux disease. Am J Gastroenterol. 2005;100:2633-2636. https://pubmed.ncbi.nlm.nih.gov/16393212/Villamil Morales IM, et al. Impact of head of bed elevation in patients with GERD (IBELGA). Gastroenterol Hepatol. 2020;43:310-321. https://pubmed.ncbi.nlm.nih.gov/32229033/Zhang Y, et al. Effect of GLP-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity. Eur J Med Res. 2026;31:318. https://pubmed.ncbi.nlm.nih.gov/41582189/Ebrahim IO, et al. Alcohol and sleep I: effects on normal sleep. Alcohol Clin Exp Res. 2013;37:539-549. https://pubmed.ncbi.nlm.nih.gov/23347102/Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA  ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

  2. 2d ago

    How to Prep the Day Before Your GLP-1 Shot to Avoid Side Effects

    #GLP1 #GLP1SideEffects #Semaglutide #Wegovy #WeightLoss One week your GLP-1 shot feels easy. The next you’re dealing with nausea, bloating, or feeling too full to eat, and you can’t figure out what changed. As a hospitalist, I’ve admitted patients whose shot week went wrong: a dose increase, days of vomiting, not enough fluids, and kidney failure. Most of those links can be planned for the day before your shot. In this video I’m Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. I walk you through a 7-step, 24-hour prep plan: what to eat, how to hydrate, what to avoid, and the red flags that mean you should call your doctor. I also tell you how strong the evidence is for each step. If you have diabetes and take insulin or a sulfonylurea, don’t skip the warning at 16:17. 🍽️ FREE GLP-1 Diet Cookbook: drmohammedpaika.com/newsletter🎓 GLP-1 Masterclass (side effects, protein, hydration, a 12-week home exercise program): drmohammedpaika.com This video is for education only and is not medical advice. Talk to your prescriber before changing your dose or routine. TIMESTAMPS0:00 When your shot week goes wrong1:33 A hospital case: dehydration and kidney failure2:38 Why I plan the day before3:26 Side effect numbers that surprised me4:03 What’s happening inside your body5:19 What the evidence can and can’t tell us5:34 Step 1: Check your dose calendar6:53 Step 2: Shrink the last big meal9:07 Step 3: Don’t go empty either10:15 Step 4: Hydrate on purpose12:21 Step 5: Alcohol and carbonation13:33 Step 6: Sleep and planning the day after14:57 Step 7: Your rescue kit15:58 Red flags: when to call your doctor16:17 Warning if you have diabetes16:49 The 24-hour plan in 30 seconds17:02 Protecting your muscle17:39 Next steps REFERENCES Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg (STEP 1–3). Diabetes Obes Metab. 2022;24(1):94-105. https://pubmed.ncbi.nlm.nih.gov/34514682/Enebo LB, et al. Cagrilintide with semaglutide 2.4 mg, phase 1b trial. Lancet. 2021;397(10286):1736-1748. https://pubmed.ncbi.nlm.nih.gov/33894838/Hjerpsted JB, et al. Semaglutide delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-619. https://pubmed.ncbi.nlm.nih.gov/28941314/Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. Am J Clin Nutr. 2025;122(1):344-367. https://pubmed.ncbi.nlm.nih.gov/40450457/Gorgojo-Martínez JJ, et al. Clinical recommendations to manage GI adverse events with GLP-1 receptor agonists: expert consensus. J Clin Med. 2023;12(1):145. https://pubmed.ncbi.nlm.nih.gov/36614945/Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA Psychiatry. 2025. https://pubmed.ncbi.nlm.nih.gov/39937469/Wegovy (semaglutide) injection Prescribing Information, Novo Nordisk, revised 05/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031,218316s00lbl.pdf ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

  3. 5d ago

    Zepbound 7.5mg to 10mg? Watch This Before You Move Up (Doctor Explains)

    #Zepbound #Tirzepatide #GLP1 #WeightLoss #ObesityMedicine Should you move up to 10 mg of Zepbound, or stay on 7.5 mg? If your weight has stalled, your hunger is creeping back, or your next box says 10 and you're not sure you need it, this video walks you through what the research actually shows. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down 4 popular claims about the 10 mg dose and give each one a verdict:1. "The drug wears off, so everyone ends up needing 10 mg"2. "10 mg is where the real results are"3. "Side effects get much worse at 10 mg"4. "Once you go up, you can't come back down" You'll see what the trials show for 5, 10 and 15 mg, how side effects compare between 5 mg and 10 mg, what the new SURMOUNT-MAINTAIN trial found about stepping down, my framework for when to stay on 7.5 mg and when to move up, and what to do before your first 10 mg shot. 🍳 FREE GLP-1 Diet Cookbook (join my newsletter): https://drmohammedpaika.com/newsletter 🎓 GLP-1 Masterclass, recently updated with a 36-week workout program that starts at home and moves to the gym: https://drmohammedpaika.com ▶️ Watch next: my video on the step from 5 mg to 7.5 mg This video is for educational purposes only and is not medical advice. Talk to your prescriber before changing your dose. TIMESTAMPS0:00 Should you move up to 10 mg?1:42 A hospital case: stuck on 7.5 mg3:16 Claim 1: "The drug wears off"5:43 Claim 2: "10 mg is where the real results are"7:36 What to eat when your appetite drops8:02 Claim 3: "Side effects get much worse at 10 mg"9:46 Claim 4: "You can't come back down"12:19 Stay on 7.5 mg or move up?13:27 Before your first 10 mg shot14:26 The pill and red-flag symptoms14:48 Recap: the 4 verdicts15:47 What the pen can't do for you REFERENCES1. ZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly and Company; revised 8/2026. https://uspl.lilly.com/zepbound/zepbound.html2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/3. Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958-971. https://pubmed.ncbi.nlm.nih.gov/39536238/4. Polidori D, et al. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity. 2016;24(11):2289-2295. https://pubmed.ncbi.nlm.nih.gov/27804272/5. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/6. Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN). Lancet. 2026;407(10545):2305-2318. https://pubmed.ncbi.nlm.nih.gov/42119587/7. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr. 2025;122(1):344-367. https://pubmed.ncbi.nlm.nih.gov/40450457/8. Gorgojo-Martínez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145. https://pubmed.ncbi.nlm.nih.gov/36614945/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

  4. Nov 5

    Zepbound 5mg to 7.5mg? Watch This Before You Move Up (Doctor Explains)

    #Zepbound #Tirzepatide #GLP1 #WeightLoss #ObesityMedicine Moving up from Zepbound 5 mg to 7.5 mg? Many people call 7.5 mg "the wall," the dose where nausea, sulfur burps and fatigue hit hard. In this video, I break down what actually changes in your body at 7.5 mg, check 4 popular claims about this dose against the prescribing information and the published trials, and share how to tell whether it's time to move up or stay on 5 mg a little longer. You'll learn:• Why 5 mg is already a full maintenance dose, not a waiting room• What the label really means by "at least 4 weeks"• Why the new dose builds over about 4 weeks instead of hitting all at once• Which side effects are common at 5 mg, and why the stomach slowing fades• The birth control pill rule most people miss• 3 changes to set up before your first 7.5 mg shot• Red flags that mean you should call your doctor 🍳 Free GLP-1 Diet Cookbook (small, lower-fat meals and protein you can get down when your appetite disappears): https://drmohammedpaika.com/newsletter 🎓 GLP-1 Masterclass (realistic expectations, side-effect management, protein and calorie targets, a 12-week home exercise program, and a plan for the long term): https://drmohammedpaika.com I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. This video is for education only and is not medical advice. Dose decisions belong with the clinician who prescribed your medication. TIMESTAMPS0:00 Moving up from 5 mg to 7.5 mg1:13 A patient story: what went wrong at 7.5 mg2:51 Claim 1: GIP "kicks in" at 7.5 mg5:19 Claim 2: 7.5 mg is where real treatment starts6:25 What to eat on injection day (free cookbook)6:50 Claim 3: You should move up every 4 weeks7:59 When to stay on 5 mg vs. move up8:45 Why hunger creeps back late in the week9:03 Claim 4: 7.5 mg hits hardest on injection day9:57 Common side effects at 5 mg10:21 Sulfur burps, reflux and slower stomach emptying11:27 Fatigue, low blood sugar and low blood pressure12:20 On the birth control pill? Read this12:45 3 changes before your first 7.5 mg shot14:36 Constipation: what to try first14:58 If 7.5 mg doesn't agree with you15:25 When to call your doctor15:40 Recap: the 4 claims scored16:36 What you need besides the pen REFERENCES1. ZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly and Company; revised 8/2026. https://uspl.lilly.com/zepbound/zepbound.html2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/3. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/4. Frias JP, et al. Efficacy and tolerability of tirzepatide in patients with type 2 diabetes: a 12-week study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938-946. https://pubmed.ncbi.nlm.nih.gov/31984598/5. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https://pubmed.ncbi.nlm.nih.gov/32730231/6. Borner T, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021;70(11):2545-2553. https://pubmed.ncbi.nlm.nih.gov/34380697/7. Borner T, et al. Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models. Sci Adv. 2025;11(25):eadu1589. https://pubmed.ncbi.nlm.nih.gov/40532005/8. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. https://pubmed.ncbi.nlm.nih.gov/40450457/9. Gorgojo-Martínez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145. https://pubmed.ncbi.nlm.nih.gov/36614945/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

  5. Nov 3

    Lower Cholesterol NATURALLY – NO PILLS - Obesity Doctor Explains

    #LDL #Cholesterol #LowerCholesterol #GLP1 #HeartHealth Can you lower LDL cholesterol without a statin? Yes, by roughly 10–15% in real life, and more if you're strict. I'm Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. In this video I show you which foods actually lower LDL, how much each one does, and when food alone isn't enough. FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber listed for every serving): https://drmohammedpaika.com/newsletterGLP-1 Masterclass (protein targets + 12-week home exercise program): https://drmohammedpaika.com TIMESTAMPS0:00 Food vs a statin: what one study found1:09 Who this video is for1:26 My LDL story2:12 Why a modest LDL drop matters2:51 The Portfolio diet study (and the catch)4:19 Step 1: Swap saturated fat for unsaturated fat5:23 Coconut oil and eggs6:03 Low-carb diets and LDL6:31 Step 2: Soluble fiber7:59 Step 3: Plant sterols and stanols8:57 Free GLP-1 Diet Cookbook9:25 Step 4: Nuts10:01 Step 5: Soy protein10:39 Step 6: Coffee, weight loss, and exercise11:22 What I see in the hospital13:08 When food isn't enough: LDL 190 or higher13:37 High lipoprotein(a)14:01 High overall risk14:32 Heart disease or diabetes14:50 Red yeast rice and supplements16:37 If statins don't agree with you17:38 GLP-1s and the SELECT trial18:23 When to recheck your lipids18:37 Summary: the plan in 30 seconds19:35 If you're on a GLP-1 REFERENCES1. Jenkins 2003, JAMA: https://pubmed.ncbi.nlm.nih.gov/12876093/2. Jenkins 2011, JAMA: https://pubmed.ncbi.nlm.nih.gov/21862744/3. Chiavaroli 2018, Prog Cardiovasc Dis: https://pubmed.ncbi.nlm.nih.gov/29807048/4. Ference 2017, Eur Heart J: https://pubmed.ncbi.nlm.nih.gov/28444290/5. CTT 2010, Lancet: https://pubmed.ncbi.nlm.nih.gov/21067804/6. Grundy 2018 guideline, Circulation: https://pubmed.ncbi.nlm.nih.gov/30586774/7. Sacks 2017, AHA advisory, Circulation: https://pubmed.ncbi.nlm.nih.gov/28620111/8. Hooper 2020, Cochrane: https://pubmed.ncbi.nlm.nih.gov/32428300/9. Neelakantan 2020, Circulation: https://pubmed.ncbi.nlm.nih.gov/31928080/10. Weggemans 2001, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/11333841/11. Soto-Mota 2024, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/38237807/12. Whitehead 2014, Am J Clin Nutr (industry-funded): https://pubmed.ncbi.nlm.nih.gov/25411276/13. Jovanovski 2018, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/30239559/14. Brown 1999, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/9925120/15. Ras 2014, Br J Nutr (industry authors): https://pubmed.ncbi.nlm.nih.gov/24780090/16. Gylling 2014, EAS consensus, Atherosclerosis: https://pubmed.ncbi.nlm.nih.gov/24468148/17. Del Gobbo 2015, Am J Clin Nutr (part industry-funded): https://pubmed.ncbi.nlm.nih.gov/26561616/18. Blanco Mejia 2019, J Nutr: https://pubmed.ncbi.nlm.nih.gov/31006811/19. Jee 2001, Am J Epidemiol: https://pubmed.ncbi.nlm.nih.gov/11207153/20. Urgert 1997, Annu Rev Nutr: https://pubmed.ncbi.nlm.nih.gov/9240930/21. Dattilo 1992, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/1386186/22. Mann 2014, Sports Med: https://pubmed.ncbi.nlm.nih.gov/24174305/23. Blumenthal 2026 ACC/AHA dyslipidemia guideline, JACC: https://pubmed.ncbi.nlm.nih.gov/41824590/24. Kronenberg 2022, EAS Lp(a) consensus, Eur Heart J: https://pubmed.ncbi.nlm.nih.gov/36036785/25. Gerards 2015, Atherosclerosis: https://pubmed.ncbi.nlm.nih.gov/25897793/26. Gordon 2010, Arch Intern Med: https://pubmed.ncbi.nlm.nih.gov/20975018/27. Sekiguchi 2026, Kidney Int Rep: https://pubmed.ncbi.nlm.nih.gov/41732753/28. Laffin 2023, SPORT, JACC (AstraZeneca-funded): https://pubmed.ncbi.nlm.nih.gov/36351465/29. CTT 2022, Lancet: https://pubmed.ncbi.nlm.nih.gov/36049498/30. Zhang 2013, Ann Intern Med: https://pubmed.ncbi.nlm.nih.gov/23546564/31. Pandor 2009, J Intern Med: https://pubmed.ncbi.nlm.nih.gov/19141093/32. Nissen 2023, CLEAR Outcomes, NEJM (Esperion-funded): https://pubmed.ncbi.nlm.nih.gov/36876740/33. Sabatine 2017, FOURIER, NEJM (Amgen-funded): https://pubmed.ncbi.nlm.nih.gov/28304224/34. Lincoff 2023, SELECT, NEJM (Novo Nordisk-funded): https://pubmed.ncbi.nlm.nih.gov/37952131/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

  6. Oct 31

    How Do I Stop Gaining Weight After Stopping Mounjaro (Doctor Explains)

    #Ozempic #GLP1 #WeightLoss #Wegovy #Mounjaro Why do most people regain the weight after stopping Ozempic, Wegovy, Mounjaro or Zepbound? As a board-certified Internal Medicine and Obesity Medicine physician, I walk through the 5 reasons weight comes back: your metabolism, your hunger hormones, stopping the medication, your activity level and not watching the scale. For each one, I go through what the research actually shows, including the Biggest Loser follow-up studies, the STEP and SURMOUNT-4 trials and a 2026 BMJ review of 37 studies. Then I share the 5-step plan that gives you the best odds of keeping the weight off, plus my own story of losing 45 pounds, regaining it and losing it again. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter TIMESTAMPS0:00 The Biggest Loser study1:26 Who this video is for2:08 My own regain story3:45 Reason 1: Your metabolism slows down4:53 Reason 2: Hunger hormones stay turned up6:04 Reason 3: The medication stops8:23 Free GLP-1 Diet Cookbook9:01 Reason 4: Activity doesn't stay high enough11:04 Reason 5: Nobody is watching the scale12:48 The plan: 5 things that give you the best odds15:57 The 30-second scorecard16:45 GLP-1 Masterclass REFERENCES1. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016. https://pubmed.ncbi.nlm.nih.gov/27136388/2. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011. https://pubmed.ncbi.nlm.nih.gov/22029981/3. Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 trial extension. Diabetes Obes Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/4. Rubino D, et al. Continued semaglutide vs placebo for weight loss maintenance (STEP 4). JAMA. 2021. https://pubmed.ncbi.nlm.nih.gov/33755728/5. Aronne LJ, et al. Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024. https://pubmed.ncbi.nlm.nih.gov/38078870/6. West S, et al. Weight regain after cessation of medication for weight management. BMJ. 2026. https://pubmed.ncbi.nlm.nih.gov/41500720/7. Kerns JC, et al. Increased physical activity associated with less weight regain six years after "The Biggest Loser." Obesity. 2017. https://pubmed.ncbi.nlm.nih.gov/29086499/8. Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33951361/9. Wing RR, et al. A self-regulation program for maintenance of weight loss (STOP Regain). N Engl J Med. 2006. https://pubmed.ncbi.nlm.nih.gov/17035649/10. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005. https://pubmed.ncbi.nlm.nih.gov/16002825/11. Jensen MD, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014. https://pubmed.ncbi.nlm.nih.gov/24222017/ This video is for education, not medical advice. Talk to your own doctor before making changes to your medication. 📚 The Weight Equation & The Physician’s PhysiquePhysician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.https://www.drmohammedpaika.com/books 👥 Metabolic Health Communityhttps://www.skool.com/metabolic-health-community-5316👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKABoard-Certified in Internal Medicine and Obesity MedicineCertified Personal Trainer & Nutrition CoachHelping people understand metabolism, hormones, and sustainable health through evidence-based medicine. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

  7. Oct 29

    I Prescribe Ozempic: Do "Natural Ozempic" Foods Actually Work?

    #ozempic #glp1 #naturalozempic #berberine #weightloss Do "natural Ozempic" foods actually work? I'm a board-certified internal medicine and obesity medicine physician, and I prescribe GLP-1 medications. In this video, I rank the 7 most popular natural Ozempic claims as real, partly real, or hype: apple cider vinegar, cinnamon, berberine, probiotics, healthy fats, eating order, protein first, and beans. You'll learn what each one can and can't do for your own GLP-1, what the human studies actually show, and which ones I use every day, whether you're on Ozempic, Wegovy, Mounjaro, or Zepbound or not. FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber per serving): https://drmohammedpaika.com/newsletterGLP-1 Masterclass: https://drmohammedpaika.com TIMESTAMPS0:00 Do natural Ozempic foods work?1:10 Why I don't trust shortcuts2:06 Your body already makes GLP-13:19 #1 Apple cider vinegar & cinnamon4:26 #2 Berberine5:52 #3 Probiotics & fermented foods7:09 #4 Healthy fats8:22 #5 Eating order9:22 #6 Protein first10:52 #7 Beans & lentils13:15 The honest answer14:28 The scorecard REFERENCESHolst 2007 Physiol Rev: pubmed.ncbi.nlm.nih.gov/17928588Drucker 2018 Cell Metab: pubmed.ncbi.nlm.nih.gov/29617641Eissele 1992 Eur J Clin Invest: pubmed.ncbi.nlm.nih.gov/1499644Mozaffarian 2025 Am J Clin Nutr (GLP-1 nutrition advisory): pubmed.ncbi.nlm.nih.gov/40450457Ozempic prescribing information: novo-pi.com/ozempic.pdfWilding 2021 NEJM (STEP 1): pubmed.ncbi.nlm.nih.gov/33567185Jastreboff 2022 NEJM (SURMOUNT-1): pubmed.ncbi.nlm.nih.gov/35658024Wilding 2022 (STEP 1 extension): pubmed.ncbi.nlm.nih.gov/35441470Johnston 2004 Diabetes Care (vinegar): pubmed.ncbi.nlm.nih.gov/14694010Kondo 2009 (vinegar, weight): pubmed.ncbi.nlm.nih.gov/19661687Liljeberg 1998 (vinegar, gastric emptying): pubmed.ncbi.nlm.nih.gov/9630389Willershausen 2014 (vinegar, enamel): pubmed.ncbi.nlm.nih.gov/24839821Allen 2013 Ann Fam Med (cinnamon): pubmed.ncbi.nlm.nih.gov/24019277de Moura 2025 Nutr Rev (cinnamon): pubmed.ncbi.nlm.nih.gov/38917435Hlebowicz 2009 (cinnamon, GLP-1): pubmed.ncbi.nlm.nih.gov/19158209Abraham 2010 (coumarin): pubmed.ncbi.nlm.nih.gov/20024932Yin 2008 Metabolism (berberine): pubmed.ncbi.nlm.nih.gov/18442638Xie 2022 (berberine meta-analysis): pubmed.ncbi.nlm.nih.gov/36467075Elahi Vahed 2026 Int J Obes (berberine, weight): pubmed.ncbi.nlm.nih.gov/41310257Guo 2012 (berberine, CYP enzymes): pubmed.ncbi.nlm.nih.gov/21870106Dumitru 2026 (berberine interactions): pubmed.ncbi.nlm.nih.gov/42653808Tolhurst 2012 Diabetes (SCFA, GLP-1): pubmed.ncbi.nlm.nih.gov/22190648Wastyk 2021 Cell (fermented foods): pubmed.ncbi.nlm.nih.gov/34256014Depommier 2019 Nat Med (Akkermansia): pubmed.ncbi.nlm.nih.gov/31263284Thomsen 1999 Am J Clin Nutr (olive oil): pubmed.ncbi.nlm.nih.gov/10357731Carr 2008 (fat, protein, GLP-1): pubmed.ncbi.nlm.nih.gov/18612044Wharton 2022 (GLP-1 GI side effects): pubmed.ncbi.nlm.nih.gov/34775881Shukla 2015 Diabetes Care (food order): pubmed.ncbi.nlm.nih.gov/26106234Shukla 2017 (carbs last, GLP-1): pubmed.ncbi.nlm.nih.gov/28989726Jakubowicz 2014 Diabetologia (whey): pubmed.ncbi.nlm.nih.gov/25005331Smedegaard 2023 (whey meta-analysis): pubmed.ncbi.nlm.nih.gov/37536867Neeland 2024 (lean mass on GLP-1s): pubmed.ncbi.nlm.nih.gov/38937282KDIGO 2024 (CKD guideline): pubmed.ncbi.nlm.nih.gov/38490803Chambers 2015 Gut (propionate): pubmed.ncbi.nlm.nih.gov/25500202Nilsson 2013 PLoS One (beans): pubmed.ncbi.nlm.nih.gov/23577078Li 2014 Obesity (pulses, satiety): pubmed.ncbi.nlm.nih.gov/24820437Kim 2016 Am J Clin Nutr (pulses, weight): pubmed.ncbi.nlm.nih.gov/27030531Winham 2011 Nutr J (beans, gas): pubmed.ncbi.nlm.nih.gov/22104320Duyff 2011 (rinsing canned beans): doi.org/10.1080/15428052.2011.582405USDA FoodData Central: fdc.nal.usda.govIOM Dietary Reference Intakes 2005: doi.org/10.17226/10490 ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

  8. Oct 27

    6 Nutrients GLP 1s May Be Depleting — A Doctor Explains Why

    #GLP1 #Ozempic #Zepbound #VitaminDeficiency #WeightLoss Taking Ozempic, Wegovy, Mounjaro, or Zepbound exactly as prescribed and still feeling more tired than you expected, noticing your hair shedding, or wondering if a multivitamin is enough? In one trial, people on semaglutide ate about 35% less at an all-you-can-eat lunch. That's why these drugs work, but less food also means less protein, fiber, vitamins, and minerals unless you choose what's left on purpose. In this video, I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down 6 nutrients you can run low on with GLP-1 medications, how strong the evidence really is for each one, and what to do about it. You'll also get a simple lab checklist to discuss with your doctor, plus the rare deficiency (#6) that can put you in the hospital. 🍳 FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber listed for every serving): https://drmohammedpaika.com/newsletter🎓 GLP-1 Masterclass (protein targets, side effects, 12-week home exercise program, what happens when you stop, plus new modules on nausea, constipation, diarrhea, heartburn, and fatigue): https://drmohammedpaika.com📩 Questions: support@drmohammedpaika.com ⏱️ TIMESTAMPS0:00 Eating less on a GLP-1? Here's the problem1:25 Why nutrients run low on these drugs2:15 #1 Protein: protecting your muscle3:23 #2 Fiber and constipation4:12 #3 Vitamin D5:36 Free GLP-1 Diet Cookbook6:05 #4 Calcium and your bones7:17 #5 Vitamin B12 (if you take metformin)8:18 Iron, magnesium, and zinc: reality check9:18 Hair loss: real, and usually temporary10:15 #6 Thiamine (B1) and Wernicke encephalopathy11:43 Red flags: when to call your doctor or go to the ER12:29 Your lab checklist13:50 Pregnancy and birth control on GLP-1s14:26 GLP-1 Masterclass 📚 REFERENCES1. Friedrichsen M, et al. Diabetes Obes Metab. 2021;23:754-62. https://pubmed.ncbi.nlm.nih.gov/33269530/2. Butsch WS, et al. Obes Pillars. 2025;15:100186. https://pubmed.ncbi.nlm.nih.gov/40584822/3. Look M, et al. (SURMOUNT-1 body composition) Diabetes Obes Metab. 2025;27:2720-9. https://pubmed.ncbi.nlm.nih.gov/39996356/4. Wilding JPH, et al. (STEP 1) N Engl J Med. 2021;384:989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/5. Mozaffarian D, et al. (ACLM/ASN/OMA/TOS advisory) Am J Clin Nutr. 2025;122:344-67. https://pubmed.ncbi.nlm.nih.gov/40450457/6. Johnson B, et al. Front Nutr. 2025;12:1566498. https://pubmed.ncbi.nlm.nih.gov/40352260/7. Wortsman J, et al. Am J Clin Nutr. 2000;72:690-3. https://pubmed.ncbi.nlm.nih.gov/10966885/8. Lai CH, et al. Arch Osteoporos. 2026;21. https://pubmed.ncbi.nlm.nih.gov/42920024/9. Beaudart C, et al. Drugs. 2026;86:1661-91. https://pubmed.ncbi.nlm.nih.gov/42730869/10. Aroda VR, et al. (Diabetes Prevention Program) J Clin Endocrinol Metab. 2016;101:1754-61. https://pubmed.ncbi.nlm.nih.gov/26900641/11. ADA Standards of Care in Diabetes—2026, Section 3. Diabetes Care. 2026;49(Suppl 1):S50-S60. https://pubmed.ncbi.nlm.nih.gov/41358891/12. Alhamdan Y, et al. Diabetes Obes Metab. 2026;28:5163-73. https://pubmed.ncbi.nlm.nih.gov/41913529/13. Shao SC, et al. PLoS Med. 2026;23:e1004968. https://pubmed.ncbi.nlm.nih.gov/41790761/14. Kanai R, et al. Obes Pillars. 2024;9:100098. https://pubmed.ncbi.nlm.nih.gov/38230266/15. Gras C, et al. Eur J Clin Nutr. 2025;79:1160-3. https://pubmed.ncbi.nlm.nih.gov/40908328/16. Bidesie J, et al. Obesity (Silver Spring). 2026;34(Suppl 2):64-9. https://pubmed.ncbi.nlm.nih.gov/42399213/17. Wegovy prescribing information (rev. 06/2026): https://www.novo-pi.com/wegovy.pdf18. Zepbound prescribing information: https://uspl.lilly.com/zepbound/zepbound.html19. Ozempic prescribing information: https://www.novo-pi.com/ozempic.pdf20. Mounjaro prescribing information: https://uspl.lilly.com/mounjaro/mounjaro.html21. NIH Office of Dietary Supplements fact sheets (vitamin D, calcium, magnesium, thiamin): https://ods.od.nih.gov/factsheets/list-all/22. American Academy of Dermatology, hair shedding: https://aad.org/hair-shedding23. Institute of Medicine, Dietary Reference Intakes (fiber), 2005: https://nap.nationalacademies.org/catalog/10490 ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

See All (125)

Ratings & Reviews

5
out of 5
2 Ratings

About

Welcome to the Dr. Paika Podcast — where medicine, fitness, and humanity come together. Hosted by Dr. Mohammed K. Paika, M.D., double board-certified in obesity & internal medicine with close to 20 years of hospital experience, this show dives deep into the science of health, obesity, longevity, and mindset — but with compassion, not complexity. From hospital medicine to the gym floor, from patient care to personal growth — every episode blends real clinical insight with practical, inspiring stories that help you live better and think deeper. 💡 Topics include: Obesity & metabolic health Longevity & fitness Nutrition & preventive medicine Doctor insights from close to 20 years in hospitals across the US! Mindset, mental health, and motivation 🎧 Subscribe for weekly conversations that are honest, empowering, and rooted in science — all from a doctor who believes medicine should heal the mind and body.

Information

  • Creator
    Mohammed Paika
  • Years Active
    2025 - 2026
  • Episodes
    125
  • Rating
    Clean
  • Copyright
    © 2026 Mohammed Paika
  • Show Website
    Dr. Paika Podcast

You Might Also Like